Marekani - Kiingereza - NLM (National Library of Medicine)

essential isotopes llc - sodium fluoride f-18 (unii: 9l75099x6r) (fluoride ion f-18 - unii:4m4we5n2ge) - fluoride ion f-18 200 mci in 1 ml - sodium fluoride f 18 injection usp is indicated for diagnostic positron emission tomography (pet) imaging of bone to define areas of altered osteogenic activity. none. pregnancy category c any radiopharmaceutical including sodium fluoride f18 injection usp has a potential to cause fetal harm. the likelihood of fetal harm depends on the stage of fetal development, and the radionuclide dose. animal reproduction studies have not been conducted with sodium fluoride f 18 injection usp. prior to the administration of sodium fluoride f 18 injection usp to women of childbearing potential, assess for presence of pregnancy. sodium fluoride f 18 injection usp should be given to a pregnant woman only if clearly needed. it is not known whether sodium fluoride f 18 injection usp is excreted into human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to interrupt nursing after administration of sodium fluo

Marekani - Kiingereza - NLM (National Library of Medicine)

hot shots nm, llc dba midwest positron technology, lc - sodium fluoride f-18 (unii: 9l75099x6r) (fluoride ion f-18 - unii:4m4we5n2ge) - fluoride ion f-18 200 mci in 1 ml - sodium fluoride f 18 injection usp is indicated for diagnostic positron emission tomography (pet) imaging of bone to define areas of altered osteogenic activity. none. pregnancy category c any radiopharmaceutical including sodium fluoride f18 injection has a potential to cause fetal harm. the likelihood of fetal harm depends on the stage of fetal development, and the radionuclide dose. animal reproduction studies have not been conducted with sodium fluoride f 18 injection. prior to the administration of sodium fluoride f 18 injection to women of childbearing potential, assess for presence of pregnancy. sodium fluoride f 18 injection should be given to a pregnant woman only if clearly needed. it is not known whether sodium fluoride f 18 injection is excreted into human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to interrupt nursing after administration of sodium fluoride f

Marekani - Kiingereza - NLM (National Library of Medicine)

biomedical research foundation of northwest louisiana - sodium fluoride f-18 (unii: 9l75099x6r) (fluoride ion f-18 - unii:4m4we5n2ge) - fluoride ion f-18 200 mci in 1 ml - sodium fluoride f 18 injection, usp is indicated for diagnostic positron emission tomography (pet) imaging of bone to define areas of altered osteogenic activity. none. pregnancy category c any radiopharmaceutical including sodium fluoride f 18 injection has a potential to cause fetal harm. the likelihood of fetal harm depends on the stage of fetal development, and the radionuclide dose. animal reproduction studies have not been conducted with sodium fluoride f 18 injection. prior to the administration of sodium fluoride f 18 injection to women of childbearing potential, assess for presence of pregnancy. sodium fluoride f 18 injection should be given to a pregnant woman only if clearly needed. it is not known whether sodium fluoride f 18 injection is excreted into human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to interrupt nursing after administration of sodium fluoride f

Marekani - Kiingereza - NLM (National Library of Medicine)

liebel-flarsheim company llc - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37) - sodium chloride .9 mg in 1 ml - - 125 ml syringe:  sodium chloride injection usp 0.9% is indicated for use in flushing compatible contrast agents through liebel-flarsheim intravenous administration sets into indwelling intravascular access devices only when delivered by the following liebel-flarsheim power injectors: angiomat® , illumena® , illumena® néo, ct9000® , ct9000® adv, optistat® , optivantage® and optistar elite. none risk summary administration of sodium chloride injection usp 0.9% is not known to cause major birth defects, miscarriage or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with sodium chloride injection usp 0.9.% all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary appropriate administration of sodium chloride injection usp 0.9% is not known to cause ha

Marekani - Kiingereza - NLM (National Library of Medicine)

fresenius kabi usa, llc - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid, unspecified form - unii:33x04xa5at), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl - this solution is indicated in patients requiring parenteral administration of potassium chloride and the replacement of extracellular losses of fluids and electrolytes with minimal carbohydrate calories. solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered. solutions containing lactate are not for use in the treatment of lactic acidosis. check flexible container solution composition, lot number, and expiry date. do not remove solution container from its overwrap until immediately before use. use sterile equipment and aseptic technique. flexible plastic container (free flex ® bag) to open - turn solution container over so that the text is face down. using the pre-cut corner tabs, peel open the overwrap and remove solution container. - check the solution container for leaks by squeezing firmly. if leaks are found, or if the seal is not intact, discard the solution. - do not use if the solution is cloudy or a precipitate is present. to add medica

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium nitroprusside, quantity: 50 mg - injection, concentrated - excipient ingredients: water for injections - sodium nitroprusside baxter concentrated injection is indicated for:,1. immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside.,2. producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate.,3. short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

Ufaransa - Kifaransa - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

reckitt benckiser healthcare france - alginate de sodium 250 mg; bicarbonate de sodium 133; carbonate de calcium 80 mg - comprimé - 250 mg - pour un comprimé > alginate de sodium 250 mg > bicarbonate de sodium 133,5 mg > carbonate de calcium 80 mg - autres medicaments pour l'ulcere peptique et le reflux gastro-Œsophagien (r.g.o) - classe pharmacothérapeutique : autres médicaments pour l'ulcère peptique et le reflux gastro-œsophagien (r.g.o), code atc : a02bx13gavisconell sans sucre menthe, comprimé à croquer édulcoré à l’aspartam et à l’acésulfame potassique forme une couche protectrice qui flotte au-dessus du contenu de l’estomac. cette couche permet d’éviter le reflux et tient le contenu stomacal éloigné de la paroi œsophagienne, soulageant ainsi la sensation de brûlures d’estomac, la sensation de gêne au niveau de la gorge et de la bouche.des brûlures d’estomac peuvent apparaitre à la suite d’un repas (par exemple après un repas riche en graisse ou épicé), ou durant la grossesse, ou encore chez des patients présentant des symptômes d’inflammation de la paroi œsophagienne (par exemple difficulté et/ou douleur à la déglutition, aphtes buccaux, vomissements).ce médicament est utilisé dans le traitement des symptômes du reflux gastro-œsophagien tels que régurgitations acides, pyrosis et digestion difficile (liée au reflux), comme par exemple, après les repas ou au cours de la grossesse, ou lors d'une œsophagite.

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

gambro lundia ab - glucose (as monohydrate); magnesium chloride hexahydrate; calcium chloride dihydrate; lactic acid; sodium chloride; potassium chloride; sodium hydrogen carbonate; calcium; magnesium; sodium; chloride; lactase; hydrogen carbonate; potassium; glucose - solution for haemodialysis/haemofiltration - 4 millimole(s)/litre - hemofiltrates

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

maco pharma (uk) ltd - potassium chloride ; sodium chloride - solution for infusion - 0.3 0.9 %w/v - electrolytes

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - potassium chloride ; sodium chloride ; glucose monohydrate - solution for infusion - 0.3/0.18/4 %w/v - electrolytes with carbohydrates